New England Biolabs GmbH was founded on April 28, 1981 as a distribution company and operates from Frankfurt am Main with an average of 42 employees (fiscal year 2023/2024) as a direct sales unit for Germany and Austria and as a service and logistics hub for Central and Eastern Europe, Turkey and the CIS states. The product portfolio comprises approximately 1,000 catalog items published in the online catalog, held in stock in Frankfurt and shipped to customers within 24 hours. Customer segments are academic research, pharma and industrial research, biotechnology and diagnostics; the focus is on enzyme‑based solutions for molecular biology applications such as PCR/qPCR/LAMP, library prep, protein production and nucleic acid purification. The company has no own production or R&D activities but supports the parent company New England Biolabs Inc. by forwarding customer requirements and market trends; it is certified to ISO 9001 and ISO 13485.
Die Einfuhr und der Vertrieb von allen Produkten, die von oder für New England Biolabs, Inc., Ipswich, Massachusetts, U.S.A., hergestellt oder gehandelt werden, sowie von ähnlichen Produkten, einschließlich von Restriktionsendonukleasen, DNS modifizierenden Enzymen sowie Phagen- und Plasmid-Desoxyribonukleinsäuren.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 54040 (as of 29 October 2026)
| Name | Type | City |
|---|---|---|
| Carsten Lanwert | Geschäftsführer(in) | Idstein |
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 54040 (as of 29 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€11.9M2 | -€438,215 | €17,194,947 | — |
| 2024 | Rohergebnis€11M2 | €1,264,145 | €20,259,746 | — |
| 2023 | Rohergebnis€9.9M2 | €575,958 | €18,801,373 | — |
| 2022 | Rohergebnis€13.8M2 | €3,224,527 | €17,672,522 | — |
| 2021 | Rohergebnis€15.2M2 | €5,541,872 | €16,580,768 | — |
| 2020 | Rohergebnis€7.9M2 | €1,211,948 | €11,242,318 | — |
| 2019 | Rohergebnis€7.2M2 | €1,238,166 | €9,385,143 | — |
| 2018 | small company1 | €2,216,327 | €5,504,325 | — |
| 2017 | small company1 | €1,712,314 | €5,770,692 | — |
| 2016 | ≤ €12M1 | €1,832,942 | €6,275,069 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Frankfurt am Main Local Court, HRB 54040 (as of 29 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,804,274 | 97.7% |
| Depreciation | €113,686 | 2.3% |
| Interest & Similar | €33 | 0.0% |
